List of Excipients in Branded Drug ZITHROMAX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pfizer Laboratories Div Pfizer Inc	ZITHROMAX	azithromycin dihydrate	0069-0400	ANHYDROUS CITRIC ACID
Pfizer Laboratories Div Pfizer Inc	ZITHROMAX	azithromycin dihydrate	0069-0400	SODIUM HYDROXIDE
Pfizer Laboratories Div Pfizer Inc	ZITHROMAX	azithromycin dihydrate	0069-3060	ALUMINUM OXIDE
Pfizer Laboratories Div Pfizer Inc	ZITHROMAX	azithromycin dihydrate	0069-3060	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
Pfizer Laboratories Div Pfizer Inc	ZITHROMAX	azithromycin dihydrate	0069-3060	CROSCARMELLOSE SODIUM
Pfizer Laboratories Div Pfizer Inc	ZITHROMAX	azithromycin dihydrate	0069-3060	D&C RED NO. 30

Generic Drugs Containing ZITHROMAX

Company	Ingredient	NDC	Excipient
DIRECT RX	azithromycin	61919-555	CELLULOSE, MICROCRYSTALLINE
DIRECT RX	azithromycin	61919-555	CROSCARMELLOSE SODIUM
DIRECT RX	azithromycin	61919-555	HYDROXYPROPYL CELLULOSE
DIRECT RX	azithromycin	61919-555	HYPROMELLOSES
DIRECT RX	azithromycin	61919-555	MAGNESIUM STEARATE
DIRECT RX	azithromycin	61919-555	MAGNESIUM TRISILICATE

What are the Most Frequently-Used Excipients in ZITHROMAX?

# Of NDCs	Excipient
2	CELLULOSE, MICROCRYSTALLINE
2	CROSCARMELLOSE SODIUM
2	HYDROXYPROPYL CELLULOSE
2	HYPROMELLOSES
2	MAGNESIUM STEARATE
2	MAGNESIUM TRISILICATE

Zithromax Excipient Strategy and Commercial Opportunities for Azithromycin Formulations

Last updated: August 8, 2026

Zithromax is Pfizer’s branded azithromycin product. Its core composition is mature, generic competition is established, and the principal commercial opportunity is no longer basic active-ingredient exclusivity. Value lies in differentiated delivery systems, pediatric acceptability, low-sugar formulations, stability improvements, contract manufacturing, and market-specific reformulation.

Azithromycin is a macrolide antibiotic approved in the United States in oral tablets, oral suspension, extended-release oral suspension, and intravenous formulations. The original active-ingredient and composition patents have expired, while regulatory protection and market exclusivity for the original product have lapsed. Excipient-led products therefore require a clear advantage in adherence, dosing convenience, tolerability, storage, or manufacturing economics.

What excipients are used in Zithromax products?

U.S. Zithromax formulations use conventional tablet, suspension, extended-release, and parenteral excipient systems. The exact composition varies by dosage form and market.

Zithromax tablets

The immediate-release tablets use excipients associated with direct compression or wet granulation, tablet disintegration, lubrication, and film coating. U.S. labeling identifies ingredients including:

• Anhydrous lactose
• Pregelatinized starch
• Magnesium stearate
• Sodium lauryl sulfate
• Hypromellose
• Triacetin
• Titanium dioxide

These excipients support tablet manufacturability, mechanical strength, disintegration, and film-coat performance. Lactose content can matter for patients with severe lactose intolerance, although the quantities in tablets are generally much lower than therapeutic dietary exposures.

The tablet platform is technically easy to reproduce. Generic manufacturers can use the same excipients or functional equivalents, provided the finished product meets pharmaceutical equivalence, bioequivalence, quality, and labeling requirements.

Zithromax powder for oral suspension

The pediatric oral suspension uses a dry powder system reconstituted with water. Labeling identifies excipients such as:

• Sucrose
• Tribasic sodium phosphate
• Hydroxypropyl cellulose
• Xanthan gum
• Colloidal silicon dioxide
• Titanium dioxide
• Flavoring agents
• Colorants, depending on strength and market

The formulation has four main technical requirements. It must disperse rapidly after reconstitution, maintain uniform azithromycin concentration during dosing, remain physically stable during the in-use period, and provide acceptable taste for children.

Sucrose provides bulk and sweetness. Xanthan gum contributes suspension viscosity. Hydroxypropyl cellulose helps control powder structure and dispersion. Tribasic sodium phosphate contributes buffering and may support chemical stability. Colloidal silicon dioxide improves powder flow and reduces aggregation.

The main commercial limitation is the sugar load. A low-sugar or sugar-free suspension could address demand from diabetes-conscious households, institutional buyers, and parents seeking lower excipient exposure. Such a product would require replacement of sucrose with a combination of polyols, high-intensity sweeteners, bulking agents, and taste-masking technology.

Zmax extended-release oral suspension

Zmax is an extended-release azithromycin formulation designed for a single-dose oral administration. Its excipient system is materially different from the immediate-release suspension and includes a matrix or controlled-release architecture. U.S. product information identifies excipients including:

• Sucrose
• Glyceryl behenate
• Poloxamer 407
• Tribasic sodium phosphate
• Hydroxypropyl cellulose
• Xanthan gum
• Colloidal silicon dioxide
• Titanium dioxide
• Flavoring agents

The commercial purpose of Zmax is dose simplification rather than a lower total azithromycin dose. The extended-release approach is relevant to adherence, particularly where a five-day course of immediate-release therapy is difficult to complete.

Zmax’s formulation presents greater technical barriers than standard azithromycin suspension. A generic or follow-on product must reproduce drug release, suspension behavior, reconstitution performance, stability, and clinical exposure. The excipient selection is therefore more commercially important than it is for conventional immediate-release tablets.

Intravenous Zithromax

The intravenous product is supplied as a sterile lyophilized powder for reconstitution and dilution before infusion. The formulation uses a relatively simple parenteral excipient system, with pH adjustment involving sodium hydroxide and citric acid identified in U.S. labeling. It does not use antimicrobial preservatives in the vial.

The main manufacturing barriers are sterile processing, lyophilization cycle control, reconstitution time, particulate control, container closure integrity, and compatibility with infusion diluents. Excipient differentiation is narrower than in oral products because parenteral safety limits the number of acceptable formulation variables.

What excipient strategies can improve Zithromax and azithromycin products?

The strongest opportunities involve pediatric acceptability, dosing simplicity, excipient reduction, and improved storage.

How can taste masking improve azithromycin suspension sales?

Azithromycin has a strong bitter taste. Taste masking is one of the most commercially relevant formulation opportunities because pediatric adherence depends on acceptance by both the child and caregiver.

Potential approaches include:

• Ion-exchange resin complexes
• Lipid or polymeric coatings
• Cyclodextrin complexes
• Microparticles or coated granules
• pH-mediated taste suppression
• Dual-sweetener systems
• Flavor systems designed for bitterness suppression rather than simple sweetness

A strong taste-masking system should preserve rapid drug release after swallowing. Coating levels that delay dissolution or increase sedimentation can create bioequivalence and dose-uniformity problems.

The most defensible commercial product would combine taste masking with a low-volume dosing regimen, an oral syringe, and a reconstitution system that minimizes caregiver error.

Is a sugar-free Zithromax suspension commercially attractive?

Yes. A sugar-free product could target pediatric patients with diabetes, dental-risk concerns, dietary restrictions, or institutional protocols that limit sucrose-containing medicines.

The technical challenge is replacing sucrose without losing:

• Palatability
• Powder bulk
• Suspension viscosity
• Dose uniformity
• Reconstitution performance
• In-use stability
• Acceptable osmolality and gastrointestinal tolerability

Possible excipient platforms include sucralose, acesulfame potassium, xylitol, sorbitol, maltitol, mannitol, microcrystalline cellulose, and modified starch. Polyols can produce gastrointestinal effects at higher doses, so the replacement system must balance sweetness, bulk, and tolerability.

A sugar-free azithromycin suspension could qualify for a 505(b)(2) development strategy if it relies on a materially different formulation and requires clinical or bridging data beyond a conventional ANDA. The regulatory pathway depends on the precise formulation and the reference product.

Can a preservative-free multidose suspension create value?

An alternative multidose suspension could use a preservative-free system supported by low water activity before reconstitution, antimicrobial packaging, a shorter in-use period, or a unit-dose presentation.

The opportunity is strongest in pediatric, hospital, and specialty pharmacy settings. The tradeoff is cost. Unit-dose sachets, stick packs, or premeasured bottles can reduce contamination but increase packaging expense.

A preservative-free product must demonstrate microbiological quality throughout the labeled in-use period. Excipients alone cannot substitute for a complete container-closure and handling strategy.

Could an orally disintegrating or dispersible azithromycin tablet compete with suspension?

A dispersible tablet could reduce the need for water measurement and improve portability. It may also reduce the volume of excipients administered to children.

Potential technologies include:

• Effervescent dispersible tablets
• Orodispersible tablets
• Mini-tablets
• Multiparticulate sachets
• Sprinkle capsules
• Fast-dispersing granules

The main risks are azithromycin’s bitter taste, dose size, friability, and pediatric swallowing ability. A multi-particulate system with coated drug particles may offer a better balance than a conventional orally disintegrating tablet.

A dispersible dosage form could be commercially stronger than another conventional suspension because it changes the administration experience rather than merely reproducing the reference product.

What patents protect Zithromax and azithromycin formulations?

The original azithromycin composition and use patents are expired in major markets. Zithromax is therefore an established generic market rather than a product protected by a current composition-of-matter patent.

What is the Orange Book status of Zithromax?

The FDA Orange Book identifies approved drug products, reference listed drugs, patents, and regulatory exclusivity where applicable. Zithromax and related azithromycin products have been subject to generic competition for many years. Current patent and exclusivity status must be assessed separately for each NDA, dosage form, and listed product in the Orange Book.[1]

The relevant U.S. products include:

Product	Dosage form	Commercial relevance
Zithromax	Immediate-release tablets	Mature generic market
Zithromax	Oral suspension	Pediatric and caregiver-focused market
Zmax	Extended-release oral suspension	Formulation-specific generic complexity
Zithromax IV	Lyophilized intravenous product	Sterile manufacturing and hospital market

A company developing a differentiated product should screen:

• Orange Book-listed patents for the selected reference product
• Expired azithromycin compound and formulation patents
• Later patents covering taste masking, particle engineering, release control, packaging, or dosing devices
• Regulatory exclusivity attached to any reformulated reference product
• Patent families in the United States, Europe, Japan, China, and other target markets

Are excipient patents available for new azithromycin products?

Yes. The active ingredient is old, but a new product may support patent claims directed to:

• Specific sweetener combinations
• Taste-masked azithromycin particles
• Controlled-release matrices
• Particle size and morphology
• Suspension viscosity ranges
• Reconstitution stability
• Low-sugar formulations
• Sachet or unit-dose packaging
• Stabilizer combinations
• Manufacturing processes
• Drug-excipient ratios
• Dosing devices integrated with the formulation

These patents are usually narrower than an active-ingredient patent. Their strength depends on unexpected performance, well-defined composition ranges, comparative data, and claim scope that cannot be easily designed around.

When does Zithromax lose exclusivity?

Zithromax lost practical market exclusivity when generic azithromycin products entered the U.S. market. The commercial transition occurred after expiration of the primary azithromycin patent estate and applicable regulatory exclusivities.

The key distinction is between:

• Compound exclusivity, which has expired
• Product-specific formulation protection, which may differ by dosage form
• Regulatory exclusivity, which is generally historical for the original Zithromax products
• New protection for later reformulations or delivery systems

A company should not assume that the expiry of an old azithromycin patent eliminates all freedom-to-operate concerns. A new product can implicate later patents on excipients, particle coating, controlled release, manufacturing, packaging, or administration devices.

What generic entry risks exist for Zithromax?

Generic entry risk is high for immediate-release tablets and conventional oral suspension. The products use familiar excipient systems, the active ingredient is well characterized, and multiple manufacturers can supply the market.

Risk is lower, but not eliminated, for:

• Single-dose extended-release suspension
• Highly taste-masked pediatric products
• Low-sugar or sugar-free products
• Unit-dose dispersible products
• Complex multiparticulate systems
• Sterile lyophilized products with difficult cycle requirements

How does the ANDA pathway affect excipient strategy?

An ANDA applicant generally seeks pharmaceutical equivalence and bioequivalence to the reference listed drug. It may use different inactive ingredients if the product meets applicable safety, quality, and performance requirements. FDA review can focus on inactive-ingredient safety, especially for pediatric and parenteral products.[2]

An excipient change can create an ANDA development issue when it affects:

• Dissolution
• Drug release
• Suspension uniformity
• Bioavailability
• Stability
• Labeling
• Allergen or intolerance considerations
• Inactive-ingredient exposure in children

For a conventional tablet, excipient substitution is usually manageable. For Zmax, release-controlling and suspension-forming excipients may be central to bioequivalence.

Which companies are competing in the azithromycin market?

The competitive field includes Pfizer as the original brand owner and generic manufacturers supplying tablets, capsules, suspensions, and injectable products. Major generic and contract-development companies have marketed azithromycin products in different jurisdictions, including Teva, Viatris, Sandoz, Sun Pharmaceutical, Cipla, Dr. Reddy’s Laboratories, Lupin, Hikma, and regional manufacturers.

Competition is segmented by dosage form:

Segment	Competitive intensity	Differentiation potential
250 mg and 500 mg tablets	Very high	Low
Immediate-release pediatric suspension	High	Moderate
Extended-release suspension	Moderate	High
Intravenous product	Moderate	Moderate
Dispersible or unit-dose pediatric products	Lower	High
Taste-masked and sugar-free products	Lower	High

The market is price-sensitive for tablets and standard suspensions. Margin potential is higher where a company can obtain physician, pharmacist, hospital, or caregiver preference through a meaningful delivery advantage.

What commercial opportunities exist for Zithromax excipient innovation?

Pediatric adherence products

The clearest opportunity is a pediatric product combining:

• Strong bitterness suppression
• Low administration volume
• Sugar-free or reduced-sugar composition
• Oral syringe compatibility
• Rapid reconstitution
• Room-temperature stability
• Clear caregiver instructions

This product could target retail prescriptions, hospital discharge medications, urgent-care settings, and global pediatric markets.

Hospital and institutional products

Hospitals may value:

• Ready-to-use oral suspensions
• Unit-dose sachets
• Reduced preparation time
• Longer in-use stability
• Barcoded packaging
• Fewer medication-preparation errors
• Preservative-free or low-excipient systems

For intravenous azithromycin, commercial opportunities are more operational than formulation-led. Ready-to-use bags, improved reconstitution, and simplified pharmacy handling could create value if the product meets hospital procurement requirements.

Emerging-market formulations

In lower-resource markets, commercial demand may favor:

• Dry suspensions with robust stability
• Sachets that reduce packaging weight
• Products that tolerate variable water quality after reconstitution
• Heat-stable formulations
• Low-cost flavor systems
• Reduced cold-chain dependence
• Flexible dose presentations

The excipient strategy must account for local manufacturing capability, supply reliability, and regulatory acceptance. A sophisticated coating technology may be less attractive than a robust, low-cost dry suspension with reliable taste performance.

Licensing opportunities

Licensing targets include:

• Taste-masking platforms with pediatric data
• Multiparticulate coating technologies
• Sugar-free suspension platforms
• Unit-dose packaging systems
• Controlled-release excipient matrices
• Ready-to-use oral liquid technologies
• Local distribution rights for differentiated azithromycin products

The strongest licensing structure would tie milestones to formulation feasibility, bioequivalence, regulatory approval, and commercial supply. A platform license without azithromycin-specific performance data has weaker negotiating value.

How strong is the patent estate for a new azithromycin excipient product?

The patent estate is weak for conventional azithromycin tablets and standard suspension because the core technology is old and widely practiced. It can be moderate to strong for a product with a narrow, data-supported formulation invention.

Patent strength improves when claims cover:

1. A specific excipient combination.
2. Defined concentration ranges.
3. A measurable taste-masking or release result.
4. Stability under challenging storage conditions.
5. A manufacturing process that is difficult to reproduce.
6. A dosage form linked to a clinically meaningful administration advantage.

Patent strength declines when claims rely only on routine excipient substitution, broad lists of conventional sweeteners, or unsupported functional language.

A commercially useful estate should include composition claims, process claims, product-by-process claims where permitted, and claims directed to packaging or administration. Geographic filing should prioritize the United States, European Patent Convention states, Japan, China, India, Brazil, and markets with substantial pediatric antibiotic demand.

What litigation and settlement risks affect azithromycin products?

Historical patent litigation affected generic azithromycin entry, particularly around the original compound and formulation patent estate. Current risk is more likely to arise from later patents covering reformulated products, manufacturing processes, particle coatings, or controlled-release systems.

A generic applicant should review:

• Paragraph IV certifications for Orange Book-listed patents
• Patent-holder litigation within the statutory 45-day period
• Any 30-month stay
• Settlement agreements restricting launch dates
• Authorized-generic arrangements
• Later-listed patents
• Patent-use codes for method-of-use claims

Method-of-use patents are less likely to block ordinary generic azithromycin use when the generic label omits the patented indication or dosing instruction. They remain relevant where the patented use is central to the commercial product.

What FDA regulatory issues apply to new Zithromax formulations?

The FDA pathway depends on how substantially the new product differs from the reference product.

An immediate-release generic tablet or conventional suspension will generally use the ANDA pathway. A materially different extended-release, taste-masked, sugar-free, or device-linked product may require a 505(b)(2) application, particularly when the sponsor relies partly on FDA findings for an approved azithromycin product but must provide new formulation or clinical data.[3]

Key regulatory workstreams include:

• Inactive-ingredient qualification
• Pediatric palatability assessment
• Dissolution and release characterization
• Bioequivalence
• Reconstitution and in-use stability
• Microbial limits
• Extractables and leachables
• Container-closure testing
• Labeling for allergens and dietary excipients
• Drug shortage and manufacturing resilience considerations

For pediatric products, taste testing, dose accuracy, dosing-device usability, and caregiver comprehension can affect commercial success even when they are not the primary patent issues.

How does Zithromax compare with competing antibiotic formulations?

Azithromycin competes with amoxicillin, amoxicillin-clavulanate, clarithromycin, cefdinir, and other antibiotics across pediatric and adult indications. Its commercial advantages include once-daily dosing, a short course for several indications, broad patient familiarity, and multiple dosage forms.

Its limitations include antimicrobial stewardship pressure, resistance concerns, gastrointestinal adverse effects, and limited differentiation in generic tablets. Excipient innovation is therefore more valuable in pediatric administration and adherence than in adult solid oral products.

Product characteristic	Azithromycin	Amoxicillin suspension	Amoxicillin-clavulanate suspension
Typical pediatric formulation challenge	Bitter taste and suspension acceptance	Taste and reconstitution	Taste, stability, and clavulanate sensitivity
Dosing convenience	Often once daily	Often multiple daily doses	Often multiple daily doses
Excipient opportunity	Taste masking, low sugar, extended release	Taste and stability	Stability, palatability, packaging
Generic price pressure	High	High	High
Differentiation potential	Moderate to high in pediatric formats	Moderate	Moderate

What is the recommended commercial strategy for Zithromax excipients?

The highest-value strategy is a differentiated pediatric platform rather than another conventional tablet.

A practical development sequence is:

1. Select a target profile combining taste masking, low sugar, and low administration volume.
2. Screen excipient combinations for bitterness suppression and rapid release.
3. Use a dry powder or multiparticulate platform to improve stability.
4. Build the formulation around a child-compatible oral syringe.
5. Generate comparative palatability, dissolution, stability, and bioequivalence data.
6. File composition, process, packaging, and device-related patent claims.
7. Select ANDA or 505(b)(2) based on formulation difference and data requirements.
8. License the product regionally where local manufacturing or distribution access is stronger than internal commercialization.

Key Takeaways

• Zithromax is a mature azithromycin brand with expired core exclusivity and substantial generic competition.
• Immediate-release tablets have limited excipient-led differentiation potential.
• Pediatric oral suspension is the strongest commercial segment for excipient innovation.
• Taste masking, sugar reduction, low administration volume, and caregiver usability are the leading opportunities.
• Zmax’s extended-release system has higher technical and regulatory barriers than conventional suspension.
• New formulation patents can be valuable, but only when supported by defined composition ranges and comparative performance data.
• ANDA is appropriate for conventional equivalent products; materially differentiated products may require 505(b)(2) development.
• Commercial returns are more likely in pediatric, institutional, unit-dose, and emerging-market products than in commodity adult tablets.
• Freedom-to-operate analysis must cover later formulation, manufacturing, packaging, and device patents, not only expired azithromycin compound patents.

FAQs

Can a sugar-free azithromycin suspension be patented?

Yes. Patentability may exist for a specific sugar-free excipient combination, taste-masking system, concentration range, manufacturing process, or stability profile. Routine substitution of sucrose with a known sweetener is less likely to support strong claims.

Is Zmax harder to develop than generic Zithromax suspension?

Yes. Zmax requires control of extended drug release, suspension behavior, reconstitution, dissolution, and bioequivalence. A standard immediate-release suspension is generally easier to reproduce.

Are excipients in Zithromax proprietary?

Most named excipients are common pharmaceutical ingredients. Commercial protection is more likely to arise from the combination, proportions, processing method, particle engineering, or packaging than from ownership of an individual excipient.

Could a taste-masked azithromycin product obtain market exclusivity?

Potentially. A new formulation that qualifies for FDA approval through an applicable pathway may receive regulatory protection, patent protection, or both. The duration depends on the approval basis and the specific innovation.

Is intravenous azithromycin a strong excipient opportunity?

The opportunity is narrower than in oral pediatric products. Value is more likely to come from ready-to-use presentation, improved reconstitution, container compatibility, sterility assurance, and hospital workflow improvements.

References

1. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

2. U.S. Food and Drug Administration. (2016). Inactive ingredient database. https://www.fda.gov/drugs/drug-approvals-and-databases/inactive-ingredient-database-download

3. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/applications-covered-section-505b2

4. Pfizer Inc. (n.d.). Zithromax azithromycin prescribing information. U.S. National Library of Medicine, DailyMed. https://dailymed.nlm.nih.gov/dailymed/

5. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/